All Activity

A California Senate committee has approved and Assembly-passed bill that would allow marijuana retailers to offer drive-thru windows to serve customers. The measure, which cleared the Senate Business, Professions and Economic Development Committee in a 7-3 vote on Monday, says that licensed cannabis retailers and microbusinesses with storefronts could sell marijuana products “to a customer in a motor vehicle in a drive-through located on the premises.” Under AB 2697 from Assemblymember Gail Pellerin (D), cannabis businesses would need approval from the local jurisdictions in which they operate in order to add the drive-thru option. The sponsor told members of the committee before the latest vote that the bill “will expand access to legal cannabis products while strengthening legal market’s ability to compete with the illicit market.” Annie Aubrey of Chuck’s Wellness Center, a retailer in Placerville, testified that the legislation “is about improving access.” “A significant portion of our customers rely on cannabis as medicine, including seniors, veterans and individuals living with chronic conditions that affect mobility—exactly the population this regulated system is meant to serve,” she said. “For many, even simple tasks like exiting a vehicle or navigating a retail space can be physically difficult or prohibitive… A drive-through option removes that barrier, allowing patients and consumers to access what they need in a way that is dignified and consistent with their health needs.” Amy O’Gorman Jenkins of the California Cannabis Operators Association said the legislation would provide “operational flexibility within a highly regulated system.” “It does not expand who can access cannabis,” she said. “It just allows retailers, with local approval, to serve existing patients and customers in a more efficient manner.” Jenkins also argued that the measure could improve safety. “Today, curbside traction transactions are already permitted. This means employees are regularly required to leave a secured premises while carrying product, and at times cash into parking lots,” she said. “AB 2697 provides an additional mechanism to attain product, but requires a fixed, secure transaction point—keeping employees inside and reducing exposure to theft.” Pellerin, the bill sponsor, previously said that “California cannabis retailers lack a common and accessible transaction path for consumers afforded so many other retailers in California, including fast food, pharmacies, banks and even liquor stores.” “Cannabis consumers who have mobility issues or other disabilities have limited options for being able to obtain cannabis without having to step out of their vehicles. And while home delivery is legal, there are service area restrictions,” she said. “Allowing cannabis retailers to add the consumer-friendly option of a secured drive through, if approved by the local jurisdiction, will enhance the consumer experience, increase safety at cannabis retailers, and help expand California’s legal cannabis marketplace.” The California Narcotic Officers’ Association opposes the proposal, however, with a representative, Ryan Sherman, testifying that it would be harder for dispensary workers to check customers’ IDs for age compliance or to detect signs of current intoxication at drive-thru windows. “This bill prioritizes speed of sale over public safety, while undermining current safeguards designed to prevent illegal sales and protect public safety,” he argued. Under a current policy enacted during the height of the COVID pandemic, dispensaries can already offer curbside pickup. The bill that is advancing in the legislature would mandate that drive-thru sales “shall occur through a fixed-pane security window with a security drawer or similar secure transfer mechanism that is part of a building located within the premises.” — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — California regulators recently adopted emergency rules changes for the state’s marijuana licensing process that are intended to make it easier for businesses to qualify for benefits in line with the Trump administration’s recent move to federally reschedule medical cannabis. Gov. Gavin Newsom (D), meanwhile, recently took credit for helping to lead the push for the state to legalize marijuana and discussed his own limited experience with using cannabis. In October, however, Newsom vetoed a bill that would have allowed certain marijuana microbusinesses to ship medical cannabis products directly to patients via common carriers like FedEx and UPS, stating that the proposal “would be burdensome and overly complex to administer.” Newsom did sign a bill earlier that month aimed at streamlining research on marijuana and psychedelics. In September, the governor also signed a measure into law to put a pause on a recently enacted tax hike on marijuana products. Separately, the state attorney general says Indian tribes cannot independently engage in marijuana commerce with licensed cannabis businesses without first obtaining their own commercial license from state officials. California officials recently awarded nearly $30 million in grants for marijuana-focused academic research projects. The post California Bill To Legalize Marijuana Dispensary Drive-Thru Windows Advances In Senate After Clearing Full Assembly appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Top marijuana officials in multiple states are taking steps to make sure that visitors who are in town to watch World Cup games understand local cannabis laws. In Massachusetts, the Cannabis Control Commission (CCC) is rolling out a public information campaign to educate soccer fans about where they can legally purchase marijuana, along with reminders about how to celebrate with it responsibly. “Our goal is to make sure both visitors and residents alike avoid committing any dangerous plays this summer while enjoying the festivities surrounding the World Cup by understanding how to consume responsibly,” CCC Chair Chris Harding said in a press release. “The Commission is committed to our public education mandate, so we encourage fans to take advantage of our resources—and in particular MoreAboutMJ.org.” CCC Executive Director Travis Ahern pointed out Massachusetts was the “first state on the East Coast to open adult-use cannabis retail stores in 2018, but legalization is still a novel concept to many nations around the world.” “For those soccer fans who choose to visit the Commonwealth to enjoy the World Cup and experience everything our state has to offer, we hope they will do so safely and responsibly,” he said. Ahead of World Cup matches, the Massachusetts Cannabis Control Commission is rolling out an educational campaign for soccer fans who choose to patronize any of the more than 400 regulated cannabis retail and delivery outlets in the state. Learn more: https://t.co/pyw2tUqfP4 — Massachusetts Cannabis Control Commission (@MA_Cannabis) June 8, 2026 In New York, the Office of Cannabis Management (OCM) is similarly putting out public messaging to help make sure tourists who are visiting to watch World Cup matches understand the basics of the state’s marijuana laws, “We certainly don’t want to see any adverse events,” John Kagia, OCM’s executive director, told The New York Post. “It’s really important to access the legal market in a responsible manner,” he said. “Be mindful and respectful and good neighbors. Be discreet. We want fans to be particularly mindful that there are young families with children at these events.” “We have great cannabis products in New York,” Kagia said. “They should not travel with cannabis outside the state.” The post State Marijuana Officials Educate World Cup Fans About How To Celebrate Legally And Responsibly While Visiting appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Idaho lawmakers have approved ballot language for a proposed constitutional amendment that would prevent voters from ever being able to decide to legalize marijuana via an initiative. The Legislative Council, a bicameral group of lawmakers, voted on Thursday to sign off on a statement of meaning and purpose for the measure, as well as arguments for and against it. If approved in November, the proposal would make it so only lawmakers could legalize cannabis or other controlled substances. Voters could also decide on the same ballot on a separate voter initiative to legalize medical marijuana after organizers last month turned in what they believe are more than enough signatures to qualify the measure. As approved by the panel last week, the statement of meaning and purpose for the measure blocking voters from legalizing marijuana reads: “In Idaho, a law may be passed by either of two methods. The first and more common method is for the Legislature to pass a law. The second, less common method allows the people themselves to pass a law through ballot initiative. This proposed constitutional amendment would give the Legislature exclusive authority to legalize marijuana, narcotics, or other psychoactive substances in the State of Idaho.” The argument in favor of the proposal says: “Drugs destroy lives, tear apart families, and threaten the safety of our communities. Decisions about legalizing marijuana, narcotics, and other psychoactive substances are too important to be made lightly. The proposed amendment would ensure that any proposal to legalize these dangerous substances would go through the legislative process. Public hearings would be held on the proposal, where law enforcement and people whose lives have been damaged by drugs would be able to testify. Legislators would carefully consider each proposal and would be publicly accountable for their votes.” The argument against the measure says: “The Idaho Constitution says that all political power belongs to the people. But the proposed amendment would take power away from the people by getting rid of their ability to pass drug legalization laws on their own through ballot initiatives. The people are as capable of making good, careful decisions about drug policy as legislators are. The amendment is also unnecessary because if the people did ever pass a poorly considered law legalizing drugs, the Legislature would have the power to amend or repeal it.” The proposed constitutional amendment, which would effectively make it illegal for voters to legalize marijuana, was approved by both chambers of the legislature earlier this year. HJR 4 says that “effective immediately upon adoption by the voters of Idaho, only the legislature of the state of Idaho shall have power and authority to legalize the growing, producing, manufacturing, transporting, selling, delivering, dispensing, administering, prescribing, distributing, possessing, or using of marijuana, narcotics, or other psychoactive substances.” If a majority of voters approve the measure on the ballot, it will be added to the state Constitution. The statement and arguments as approved by the Legislative Council last week will now head to the secretary of state, who will include them in a pamphlet that is mailed to every household in the state. At the same time, an Idaho medical marijuana campaign announced last month that it turned in more than 150,000 signatures for a proposed legalization initiative it wants to qualify for the state’s November ballot. County clerks across the state have until June 30 to verify the signatures submitted by the Natural Medicine Alliance of Idaho (NMAI) and report to the secretary of state’s office. At this stage, it’s unclear how many signatures the campaign has collected far are valid and whether activists have met a separate requirement for regional distribution of petitions. To be certified for the ballot, the team needed to submit signatures from at least 6 percent of registered voters as of the state’s last general election, which currently amounts to 70,725. They also needed to meet that 6 percent threshold in at least 18 of the state’s 35 legislative districts. While NMAI has pursued ballot access, Idaho lawmakers have pushed back. In addition the proposed constitutional amendment, both the Senate and House of Representatives passed a resolution this session urging voters to “reject” the medical marijuana petition. The measure, sponsored by the Senate State Affairs Committee, claims that cannabis legalization in other states has led to a host of harms, including “increased cartel activity, development of black market marijuana production, human trafficking, and increased crime rates” as well as “increased rates of serious health issues,” environmental harms and “safety concerns on job sites.” It argues that the marijuana initiative would not only increase costs to the state but that its list of approved medical conditions is “so broad that almost anyone could qualify.” “The Idaho Medical Cannabis Act lacks safeguards to such an extent that it would effectively legalize widespread recreational use of marijuana,” the resolution claims. “The legalization of marijuana would have devastating impacts on Idaho children and their families… The Legislature urges the citizens of Idaho to reject any effort to bring the Idaho Medical Cannabis Act to the ballot.” A statement of purpose filed with the legislation says it “addresses the devastating impact that legalizing marijuana has had on other states” and “identifies the significant problems” with the ballot initiative. Contrary to the claims made about marijuana reform in the legislative resolution, advocates often point to data showing that legalizing and regulating cannabis diminishes the size of the illegal market and has not led to increases in youth use. Meanwhile, NMAI recently released an analysis showing that Idaho could see more than $100 million worth of medical marijuana sold on an annual basis and up to $28 million in new yearly revenue for state coffers if voters approve the legalization initiative. The Idaho Medical Cannabis Act, which NMAI unveiled last October, would provide patients with qualifying conditions access to marijuana from a limited number of dispensaries and provide a regulatory framework for the market. Here are the main provisions of the Idaho Medical Cannabis Act: Health practitioners would be able to recommend medical cannabis to patients with conditions that include, but are not limited to, cancer, anxiety and acute pain. Medical marijuana patients or their designated caregiver could purchase up to 113 grams of smokeable cannabis, or 20 grams of THC extract for vaping, per month. The state would be start by issuing three vertically integrated cannabis business licenses, after which point it could license up to six total. Marijuana would be reclassified under state law as a Schedule II, rather than Schedule I, controlled substance. State and local law enforcement would be barred from assisting in federal drug enforcement activities related to the state-legal cannabis program. There would be anti-discrimination protections for those who use or sell marijuana in compliance from state law, preventing adverse actions by employers, landlords and educational institutions. It does not appear that there would be any equity-centered reforms, nor would the initiative provide for a home grow option. “We believe Idahoans deserve access to legal, compassionate, natural care right here at home,” NMAI’s website says. “Our mission is to give patients a legal pathway to natural medicine that can ease suffering and restore dignity without the fear of addiction.” “The Idaho Medical Cannabis Act is our first step forward. It creates a safe, tightly regulated medical program that allows qualified Idahoans to seek medical cannabis treatment with a valid diagnosis from a healthcare provider,” it says. “It supports Idaho agriculture, generates tax revenue to reinvest locally, and ensures that patients can find natural relief.” The campaign in February also released the results of a statewide poll showing that 83 percent of likely voters back medical cannabis legalization, including 74 percent of Republicans, 95 percent of Democrats and 92 percent of independents. Asked how they would vote if the current medical cannabis legalization does appear on the November ballot, 76 percent of respondents said “yes.” Of that cohort, 50 percent said they would “definitively” vote yes, and just 21 percent said they’d vote “no.” After the medical cannabis initiative was unveiled last year, a separate campaign that launched in 2024, Kind Idaho, told supporters that it would be suspending its own signature gathering for a ballot initiative to legalize the personal possession and cultivation of marijuana by adults. Kind Idaho previously introduced medical marijuana ballot measures intended to go before voters in both the 2022 and 2024 elections, but the efforts proved unsuccessful. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — Legislators separately held a hearing last year to discuss a bill to enact medical cannabis legalization legislatively, but it did not advance. Idaho Gov. Brad Little (R) last year signed legislation setting a $30o mandatory minimum fine for marijuana possession. A prior version of the proposal, which did not pass, would have set a $420 mandatory minimum fine for possessing cannabis. Photo courtesy of Philip Steffan. The post Idaho Lawmakers Approve Ballot Language For Measure To Block Voters From Legalizing Marijuana appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

“With rescheduling, it is possible that medical cannabis operations might have similar success filing a chapter 11 in the near future.” By Michael Brandess and Steve Levine, Husch Blackwell LLP The cannabis business can be challenging. Margins are often pretty thin. Customers are fickle. And taxes are pretty high. While other industries have similar problems, until the recent rescheduling of medical marijuana, the industry had been completely frozen out of U.S. bankruptcy courts because it was federally illegal, and bankruptcy law is federal law. To some extent, however, that recently changed. On March 24, The Cannabist Company Holdings (Canada) Inc. and its U.S. subsidiaries commenced proceedings under the Companies’ Creditors Arrangement Act (CCAA) in Canada, which has similarities to Chapter 11 under U.S. bankruptcy law. The next day, Cannabist initiated a Chapter 15 bankruptcy proceeding in the District of Delaware. The Cannabist Chapter 15 is the first instance of an operating U.S. cannabis business successfully availing itself of U.S. bankruptcy protections, albeit indirectly through the Canadian proceeding and without the full menu of benefits typically available to companies undergoing Chapter 11. Chapter 15 of the U.S. bankruptcy code allows for “recognition” of cross-border insolvency proceedings. Recognition occurs when a company undergoing an insolvency proceeding in a foreign country (e.g., Canada) has assets in the U.S. Chapter 15 allows that company to open an ancillary proceeding in which U.S. bankruptcy courts can grant judicial comity to the reorganization or liquidation ongoing in the foreign country. There was a meaningful question at the onset of Cannabist’s filing as to whether Bankruptcy Judge Brendan Shannon would “recognize” the chapter 15, as U.S. bankruptcy law grants him authority to refuse recognition of the foreign proceeding. That would have left Cannabist’s U.S. subsidiaries exposed to considerable and near-immediate creditor collection activity. But with minimal creditor pushback, the judge quickly granted provisional relief, previewing his inclination to allow the proceeding to move forward. On May, he entered a final order granting recognition and implementing a sweeping stay against creditor collection activity. Although a cannabis business utilizing a complicated restructuring process inclusive of U.S. bankruptcy law is exciting for a particularly narrow subset of people, the business implications are far-reaching. Over the past few years, numerous U.S. cannabis businesses have suffered considerable financial distress. Companies like Schwazze, MedMen, PharmaCann, AYR Wellness and others have undergone receiverships, foreclosures or comprehensive restructurings with their lenders. Many of those businesses had Canadian affiliates or parent companies, and it’s likely that Cannabist will provide a roadmap for similarly situated entities in the future. To appreciate the implications of the Cannabist Chapter 15, it’s important to understand what cannabis companies have been missing. Business bankruptcy often carries a negative connotation. It is psychologically correlated with financial ruin and business failure. And while financial distress is often attendant to bankruptcy, it is only part of the story. U.S. bankruptcy law is intended to provide troubled companies with a breathing spell from their creditors to allow for reorganization or an organized wind down. This breathing spell comes in the form of an “automatic stay,” which is effectively an injunction preventing creditors from seeking collection of their debts or landlords and contract counterparties from terminating their leases and contracts during the bankruptcy proceeding. But U.S. bankruptcy cases are federal proceedings. The cases are overseen by federal judges rather than those elected or appointed in the individual states. U.S. bankruptcy law is federal law, although it incorporates state law in certain instances. But there is good reason to think that the federal government is taking a different approach to cannabis than it has in the past. In December 18, President Donald Trump signed an executive order directing federal agencies to expedite the reclassification of marijuana. The resulting rescheduling move undertaking by the Department of Justice immediately pertains to medical, not recreational, cannabis; and accordingly, not all facets of the industry will enjoy the benefits of this regulatory change for now. Even after rescheduling of medical marijuana, adult-use marijuana is still federally illegal as a Schedule I substance. Accordingly, cannabis businesses in the U.S. have previously been precluded from obtaining bankruptcy relief. When they have tried in the past, DOJ’s bankruptcy watchdog, the U.S. Trustee, has zealously, and in most cases successfully, opposed cannabis businesses from obtaining U.S. bankruptcy protection. In addition to being deprived of U.S. bankruptcy relief, cannabis businesses have also largely been restricted from obtaining standard bank loans. Many U.S. banks won’t risk lending to federally illegal businesses. As such, the cost of capital for most cannabis businesses (e.g., interest rates and other fees) has been higher than for non-cannabis businesses. And despite continued market growth, profit margins are squeezed by operational challenges, significant regulatory compliance costs and heightened tax burdens at the state and federal levels. Compressed profit margins for certain operators mean low margins for error without the risk of loan defaults and liquidity problems. And so, when cannabis businesses have had trouble in the past, unlike most U.S. businesses, they have had to seek alternative means of reorganizing their businesses or liquidating their assets. For instance, MedMen had operations across the country. A non-cannabis company with a footprint similar to MedMen would typically have sought chapter 11 bankruptcy relief because a federal court in one state could oversee the reorganization or liquidation of assets across the country. But MedMen, like many before and after, filed a receivership in California, necessitating a more complicated winddown process. The U.S. cannabis industry enjoys more than $30 billion in annual revenues and maintains tens of thousands of jobs. From a corporate insolvency perspective, businesses in this industry deserve the same opportunity afforded to non-cannabis businesses to turnaround and restructure their companies. Patchwork regulations between states and federal half-measures, such as rescheduling for a subset of the industry, create considerable confusion for multistate and cross-border operators. Companies in distress need as much certainty as possible. While the Cannabist development does not provide complete access to U.S. bankruptcy law, it is a meaningful step forward. Following Cannabist, there is now a backdoor to U.S. bankruptcy courts for companies with foreign parent companies or affiliates. It is another potential lifeline for businesses with similar corporate and financial structures as Cannabist. Additionally, with rescheduling, it is possible that medical cannabis operations might have similar success filing a chapter 11 in the near future. But alas, these attorneys can only hope for so much excitement at one time. Steve Levine is a partner and leader of the Financial Services & Capital Markets industry group and co-leads the national Cannabis practice at Husch Blackwell LLP, focused on guiding MSOs, investors and entrepreneurs through complex transactions and strategic growth initiatives in the cannabis industry. Michael Brandess is a corporate restructuring partner at Husch Blackwell LLP, helping businesses, their owners and their creditors manage the complexities associated with financial distress and bankruptcy law. The post Court Ruling Provides ‘Backdoor’ Access To Bankruptcy Relief For Some Marijuana Companies As Rescheduling Unfolds (Op-Ed) appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE CLICK HERE

Federal marijuana trafficking cases fell to another record-low in 2025, with a new report from the U.S. Sentencing Commission (USSC) revealing a continued trend amid the expanding state-level reform movement that has given consumers more places to buy legal cannabis. A recently published USSC fact sheet on drug prosecution trends shows just 383 federal cannabis trafficking cases in the last fiscal year. That marks a decline from the 471 cases reported in 2024. More broadly, USSC said, marijuana trafficking prosecutions have dropped 62 percent from fiscal year 2021 to 2025. Shifting federal priorities, which seem to have coincided with state-level marijuana reform efforts, have gradually pushed cannabis near the bottom of the list of drug trafficking cases. The 383 cases from last year stands in stark contrast to the nearly 3,500 cannabis trafficking cases that were reported in 2015. Just two years before that, in 2013, the marijuana prosecutions amounted to approximately 5,000. Colorado and Washington State became the first two states to approve recreational marijuana legalization in 2012. Methamphetamine trafficking cases have dominated the list over the past decade, the USSC document published last month shows. In 2024, cases targeting fentanyl took over as the second most common drug trafficking target, followed by crack cocaine and powder cocaine. The number of heroin trafficking cases (356) was marginally lower than marijuana last year. A separate USSC data tool shows that the number of people sentenced in federal courts for drug trafficking or possession involving marijuana has declined from 5,554 in 2015 to just 400 last year. Advocates for cannabis legalization have long argued that providing access to regulated marijuana markets for adults would drive down demand for unlicensed products, translating into less illegal trafficking and fewer arrests for illicit production and sales. The latest USSC data continues to reinforce that argument by illustrating a gradual decline in federal cannabis trafficking cases as more states have enacted legalization. USSC’s 2025 Sourcebook of Federal Sentencing Statistics, published in April, separately notes that of all federal drug cases last year—for manufacture, sale and transportation—cannabis accounted for about 2.4 percent. Criminal sentences were also lowest for marijuana among all drug trafficking cases, averaging 44 months—representing an increase from the average 36 months in last year’s report. Via USSC. Notably, federal guidelines from USSC advising judges to treat prior marijuana possession offenses more leniently officially took effect in late 2023. Federal judges have historically been directed to take into account prior convictions as aggravating factors when making sentencing decisions in new cases. But as more states have moved to legalize marijuana, advocates had pushed for the updated guidelines to make it so that a person’s cannabis record didn’t necessarily add criminal history points that could lead to enhanced sentences. USSC also released a report in 2023 showing that hundreds of people received more serious federal prison sentences in the prior fiscal year because of cannabis possession convictions in states that have since reformed their marijuana laws. What remains to be seen is whether recent changes in federal marijuana laws under the Trump administration will translate into further declines in cannabis-related prosecutions. The Justice Department last month moved medical cannabis authorized under state programs from Schedule I to Schedule III of the Controlled Substances Act (CSA), and that reclassification could be expanded depending on the outcome of a pending administrative hearing process. Meanwhile, a coalition of Democratic members of the U.S. House of Representatives and Senate are pushing President Donald Trump to commute the sentences of people who are still serving time in federal prison for marijuana. The move, they say, is a logical next step amid the rescheduling actions. For what it’s worth, marijuana arrests are driving the overall war on drugs in states where cannabis remains illegal, according to a 2025 NORML analysis of FBI data. And most of those busts are for simple possession. Data from U.S. Customs and Border Protection (CBP) in 2024, meanwhile, showed that seizures of cannabis at southern border declined again in 2023, as the state marijuana legalization movement continued to expand. The post Federal Marijuana Prosecutions Hit Another Record Low In 2025 As State Legalization Expands, Government Report Shows appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

I think that thanks for the valuabe information and insights you have so provided here. 모바일맞고

Very informative post! There is a lot of information here that can help any business get started with a successful social networking campaign. 인디고 게임

VA gov & lawmakers’ “fruitful” marijuana negotiations; Cannabis & workers’ comp; Medicare CBD lawsuit dismissal appealed Subscribe to receive Marijuana Moment’s newsletter in your inbox every weekday morning. It’s the best way to make sure you know which cannabis stories are shaping the day. Get our daily newsletter. Email address: Leave this field empty if you're human: Your support makes Marijuana Moment possible… Your good deed for the day: donate to an independent publisher like Marijuana Moment and ensure that as many voters as possible have access to the most in-depth cannabis reporting out there. Support our work at https://www.patreon.com/marijuanamoment / TOP THINGS TO KNOW The White House Office of Management and Budget is urging Congress to “update the statutory definition of final hemp-derived cannabinoid products to allow Americans to benefit from access to appropriate full-spectrum CBD products” while restricting “products that pose serious health risks.” The House Appropriations Subcommittee on Labor, Health and Human Services, Education, and Related Agencies approved a funding bill blocking federal workers’ compensation programs from covering medical cannabis—”regardless of any change in the scheduling of marijuana.” A coalition of anti-marijuana groups and a cannabis-focused biopharmaceutical corporation are appealing the dismissal of their lawsuit challenging a Centers for Medicare & Medicaid Services plan to cover hemp products for eligible patients to the U.S. Court of Appeals for the District of Columbia Circuit. Virginia lawmakers and Gov. Abigail Spanberger (D) have had “very fruitful” conversations about a compromise approach to legalizing recreational cannabis sales that could pass this month as part of budget legislation, a key lawmaker told Marijuana Moment. A spokesperson for the governor told Marijuana Moment that she “looks forward to moving this across the finish line together” with the sponsors of earlier cannabis commercialization legislation she vetoed. The Michigan House Families and Veterans Committee held a hearing on a bill to create an ibogaine grant program to support research on whether the psychedelic is effective in treating substance use disorder and other mental health conditions—using $50 million in opioid settlement funds. Missouri Republican lawmakers are hopeful that President Donald Trump’s recent psychedelics executive order boosts efforts in the state to allow military veterans to get therapeutic access to psilocybin and ibogaine. / FEDERAL Agriculture Secretary Brooke Rollins said in response to a hemp question from Rep. Jim Baird (R-IN) at a hearing that they should meet to discuss the issue. / STATES Colorado Gov. Jared Polis (D) signed a bill to revise how marijuana tax revenue is allocated. New Jersey Gov. Mikie Sherrill (D) signed a bill allowing large-size hemp drinks and letting medical cannabis dispensaries add recreational sales without local approval. Iowa Democratic gubernatorial candidate Rob Sand said revenue from legalizing marijuana could help avert a “fiscal time bomb” the state is facing. Kansas Republican gubernatorial candidates agreed on opposition to legalizing medical cannabis during a debate. A Texas court stayed an injunction on hemp product restriction rules, allowing them to go into effect pending ongoing litigation. Hawaii regulators are being sued over hemp product restrictions. California regulators announced a recall of marijuana products due to the presence of aspergillus. They also adopted emergency rules allowing cannabis businesses to modify their license designations. Michigan wholesale marijuana tax revenue is falling short of projections. Alabama regulators published a list of doctors registered to issue medical cannabis recommendations. / LOCAL Jersey City, New Jersey officials dropped a federal lawsuit seeking to uphold the city’s ability to fire police officers for off-duty marijuana use. Las Vegas, Nevada police are collaborating with a cannabis business on a training program to help officers identify marijuana-impaired driving. / INTERNATIONAL Mexican President Claudia Sheinbaum accused the U.S. of meddling in the country’s affairs amid investigations into sitting governors’ potential ties to drug cartels. / SCIENCE & HEALTH A study found that “CBD ingestion has prosexual effects, mainly manifested in sexual motivation, on both sexually competent and sexually inhibited male rats, while chronic CBD treatment does not produce unwanted sexual effects in the sexually competent males.” A review concluded that “the serotonergic psychedelics have therapeutic potential in the treatment of anxiety, especially psilocybin elicited consistent anxiolytic-like effects, possibly due to 5-HT2A receptor agonism.” / BUSINESS Trulieve Cannabis Corp. will begin trading on the New York Stock Exchange on Wednesday. TerrAscend Corp. is asking shareholders to approve share consolidation in preparation for potential uplisting to a U.S. stock exchange. Texas Original Compassionate Cultivation is suing other businesses for allegedly selling illegal marijuana under the guise of hemp. Make sure to subscribe to get Marijuana Moment’s daily dispatch in your inbox. Get our daily newsletter. Email address: Leave this field empty if you're human: Photo courtesy of Chris Wallis // Side Pocket Images. The post White House pushes Congress to keep some hemp products legal (Newsletter: June 8, 2026) appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

A clear and informative article that keeps readers engaged from start to finish. The presentation style is simple, practical, and easy to follow. During my search for Escort in South Ex your content appeared more structured and insightful than many other sources.

Hello, I have browsed most of your posts. This post is probably where I got the most useful information for my research. Thanks for posting, maybe we can see more on this. Are you aware of any other websites on this subject. แทงบอล

I think this is an informative post and it is very useful and knowledgeable. therefore, I would like to thank you for the efforts you have made in writing this article. แทงบอล

You completed a few fine points there. I did a search on the subject and found nearly all persons will go along with with your blog. แทงบอล

Your authoring on content pertaining to corporate sensibility is commendable. Superior working skills, and I anticipate your Survival race forthcoming writings on this subject.

“Kudos to President Trump for stepping up and taking the lead on this. PTSD is really a killer among veterans.” By Rebecca Rivas, Missouri Independent Missouri state Rep. Dave Griffith has spent the last five years digging into research on how psychedelic-assisted therapy has helped veterans struggling with post-traumatic stress disorder and depression. This May marked the end of his final legislative session in the House, and he pushed one last time for legislation to allow clinical trials of psychedelic-assisted therapy in Missouri. In the final days of session, the bill stalled in the Missouri Senate, after passing with overwhelming support in the House. “I’m not going to be there next year, I’m term-limited out,” said Griffith, a Republican who served as chairman of the House Veterans and Armed Forces Committee. “It’s really passing the torch to a lot of the other veterans that are on the Veterans Committee and those that see the value in it.” He was hopeful when he saw an announcement from the U.S. Department of Veterans Affairs last week for a new clinical trial to evaluate the safety and efficacy of methylenedioxymethamphetamine-assisted therapy, or MDMA-assisted therapy. MDMA is a synthetic substance made in a lab, according to the department, and it’s also called “ecstasy” or “molly” in recreational use. “Kudos to President Trump for stepping up and taking the lead on this,” said Griffith of Jefferson City. “PTSD is really a killer among veterans. If you listen to the testimony that’s been taking place over the last five years just in the Missouri House alone, the life change that it’s had for them is a really compelling reason why something like this would work.” The new trial comes after Trump signed an executive order in April titled, “Accelerating Medical Treatments for Serious Mental Illness.” The order aims to increase clinical trial participation and accelerate innovative research models and drug approvals for psychedelic drugs. It orders the secretary of health and human services to allocate at least $50 million to support and partner with state governments “that have enacted or are developing programs to advance psychedelic drugs for serious mental illnesses.” Without passing legislation, Missouri will miss out on this opportunity, said Republican state Rep. Matthew Overcast of Ava. Overcast was hopeful Trump’s April order would’ve helped “grease the wheels” on legislation he and state Rep. Richard West sponsored this year to require the state to conduct a study on psilocybin- and ibogaine-assisted therapy. “There’s been a lot of federal moving on things that the states have been reluctant to move on here in the last couple of months,” Overcast said. “So that’s exciting.” According to the VA’s announcement, the department is involved in 19 other active clinical trials focused on psychedelic therapies for mental health conditions that are supported by more than $23 million in external funding. The new trial, titled “A Randomized Controlled Trial of MDMA-Assisted Therapy for PTSD and Alcohol Use Disorder in U.S. Veterans,” will enroll approximately 80 veterans and compare outcomes between those receiving MDMA-assisted therapy and those receiving identical psychotherapy with an active placebo. The VA is coordinating with the U.S. Food and Drug Administration and intends to share data from the trial with FDA. The trial will take place at VA Providence Healthcare System, and recruit veterans from the Providence, Rhode Island, campus and VA Connecticut Healthcare System in West Haven, Connecticut. Trump’s executive order states that for over 20 years there have been more than 6,000 veteran suicides per year, and the current veteran suicide rate is more than twice as much as the non-veteran adult population. Individuals, it says, suffering from major depressive disorder and substance abuse disorder, among other serious mental illnesses, can relapse or not fully respond to standard medical and psychiatric therapies. “Despite massive federal investment into researching potential advancements in mental health care and treatment, our medical research system has yet to produce approved therapies that promote enduring improvements in the mental health condition of these most complex patients,” the order states. “Innovative methods are needed to find long-term solutions for these Americans beyond existing prescription medications.” Missouri veterans John and Kara Grady, who own a hemp store in Rosebud wholeheartedly agree with the statement, they said. And they’d love to see Missouri veteran healthcare systems taking part in the clinical trials already underway. “President Trump’s really been opening up the research for the veteran community,” John Grady said, “If you look at the numbers…we’ve lost more to mental health than we’ve lost to wars.” The lack of movement on legislation for psychedelic-assisted therapy is among the reasons John Grady is running for state representative, against incumbent state Rep. Bruce Sassmann in the Republican primary. “If you disagree with Trump on all kinds of things, at least he’s addressing this issue right here that pertains to veterans,” Grady said. “Hopefully, we can stop that number, stop that flow of our precious veterans dying just at their own hands because they don’t have treatment.” This story was first published by Missouri Independent. The post Missouri GOP Lawmakers Hope Trump’s Psychedelics Order Boosts Efforts To Allow Military Veteran Access In The State appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Very useful info. Hope to see more posts soon!. เว็บแทงบอล

Wow i can say that this is another great article as expected of this blog.Bookmarked this site.. slot88

I am impressed. I don't think Ive met anyone who knows as much about this subject as you do. You are truly well informed and very intelligent. You wrote something that people could understand and made the subject intriguing for everyone. Really, great blog you have got here. wopslot

This is very educational content and written well for a change. It's nice to see that some people still understand how to write a quality post! เว็บแทงบอลออนไลน์

Awesome article, it was exceptionally helpful! I simply began in this and I'm becoming more acquainted with it better! Cheers, keep doing awesome! แทงบอลมือถือ

Your content is nothing short of brilliant in many ways. I think this is engaging and eye-opening material. Thank you so much for caring about your content and your readers. สมัครแทงบอล

I have read your article, it is very informative and helpful for me.I admire the valuable information you offer in your articles. Thanks for posting it.. เว็บแทงบอลออนไลน์

“For many veterans, the battle does not end when they come home. Too many carry the invisible wounds of service.” By Ben Solis, Michigan Advance Can a psychedelic drug with heavy side-effects and anecdotal evidence as a treatment for addiction become a wonder drug for veterans facing opioid substance abuse and post-traumatic stress disorders? House Republican state Rep. Jaime Green of Richmond wants to find out, and she wants to use opioid settlement dollars to fund necessary clinical trials—a proposal that might meet some resistance from her Democratic colleagues. Members of the House Families and Veterans Committee discussed Greene’s House Bill 6020 on Tuesday. The committee included testimony from proponents of ibogaine as a therapeutic addiction and trauma drug. The committee took testimony only and did vote on Greene’s bill. Ibogaine is currently outlawed in the United States and is considered a Schedule I controlled substance. It is a potent psychedelic with a prolonged experience sometimes lasting more than 12 hours. Those who testified on Tuesday said the drug is physically and mentally intense, as an ibogaine experience has been likened to Indigenous ancient spirit journeys with waking visions. It also carries heavy cardiovascular risks, and requires attentive medical monitoring by licensed professionals when used in a clinical setting. Much of the research being conducted into ibogaine as a therapeutic drug has been done in other nations that have allowed trials, like Mexico. Greene, a former U.S. Navy cryptologist, said she has not tried the therapy, but has heard of its potential at conferences. “For many veterans, the battle does not end when they come home. Too many carry the invisible wounds of service, post-traumatic stress, traumatic brain injury, depression, chronic pain, substance abuse disorder,” Greene told the committee. “In some cases opioid dependence begins with an injury, a prescription to manage the pain or the trauma. So, Michigan has a responsibility to stand with the men and women who serve this country, and that means honoring their service with more than words.” Greene’s bill would create an ibogaine grant program supporting research to see if the psychedelic is effective in treating substance use disorders and other conditions, like trauma-related mental illnesses. If approved as written, HB 6020 would give the Michigan Department of Health and Human Services authority to establish a consortium of other states, drug manufacturers, health facilities and research-focused universities to conduct the research. An ibogaine research fund would be established to drive dollars to the program with a proposed $50 million appropriation. The House Fiscal Agency notes that the fund would be created by the state Department of Treasury. The $50 million appropriation would come from the Michigan Opioid Healing and Recovery Fund—the state’s restricted account that holds a portion of the $1.8 billion received by Michigan from the national opioid settlement of a class-action lawsuit. That last bit could prove controversial and might make some of Greene’s colleagues on the committee wary of advancing the legislation. She was adamant that the bills would not legalize ibogaine for recreational use, nor would it impact current projects being funded by the opioid settlement fund. State. Rep. Mai Xiong (D-Warren) noted that the state has barely, if ever, funded clinical trials on experimental drugs, and that the funding would largely come from dollars set aside to not only treat opioid addiction using proven methods, but to also heal the wounds communities have endured due to rampant opioid use and damage caused by the pharmaceutical industry pushing those drugs on vulnerable populations, much like veterans. Xiong argued that the funds should be used for those more proven methods and not clinical trials. Greene responded that there hasn’t been a substance like this with so much promise, and that Michigan has state of the art research facilities that have the capacity to embark necessary trials to learn if ibogaine can be put to good use. “University of Michigan is a great example of that. That is a top global research facility that we should be having here in Michigan to not just help our veterans, but also those who are addicted to opioids,” Greene said. “Why wouldn’t we want to do that? We have a fund that is supposed to be used to help people with opioid addiction. This is actually, instead of just handing out pamphlets, this actually gives them an opportunity to be able to receive healing.” Kevin Boehnke, an assistant professor in anesthesiology and the associated director of the Michigan Psychedelic Center, spoke in support of the legislation. Boehnke said the center’s mission is to advance education and research on psychedelics as medical treatments, and is currently conducting trials on cannabis among veterans with chronic pain. Boehnke added that ibogaine, which originates in West and Central Africa, has been used for centuries by native tribes, and that interest in the drug for therapies came about in the last few decades. “Unlike conventional medicines that require daily dosing, some evidence suggests that a single ibogaine administration may improve symptoms for an extended amount of time,” he said. “Despite these known restrictions, there is some scientific literature that shows some potentially compelling benefits, especially for our veteran community.” Boehnke went on to say that veterans face disproportionately higher rates of traumatic brain injury, post-traumatic stress disorder, opioid and other substance use disorders, as well as battles with chronic pain and suicide. “While current treatment options are useful for some individuals, they leave too many service members without adequate relief,” Boehnke said. Still, state Rep. Carrie Rheingans (D-Ann Arbor) remained skeptical. In a separate interview with Michigan Advance, Rheingans said she was unsure that the parameters of the opioid settlement fund allowed for clinical trials on addiction treatment drugs. She also said that most legislators have no experience doing clinical research and that they often don’t understand what goes into it. “They don’t know how much it is to do it right, and to get scientific evidence,” Rheingans said. “It may sound like a good idea to spend some opioid settlement dollars to try and learn more about treating veteran PTSD. … I think that the anecdotes that we heard and the personal stories demonstrate that ibogaine can be a miracle for some people with their conditions. I’m not saying that that’s not true, but in order to prove it scientifically, we need multiple years of clinical trials, and those are best financed through federal funding sources.” Rheingans said it would be more appropriate for the federal National Institute of Health or the U.S. Department of Veterans Affairs to step up and fund the research. She also criticized her Republican colleagues for suggesting that the state fund the research, considering federal sources could have been an option if they didn’t see recent massive cuts under the administration of President Donald Trump. As to whether the settlement funds could be used for clinical trials, Rheingans said she believes that would be less a question for Michigan’s lawmakers and more so for Attorney General Dana Nessel. She also noted that the Legislature created a legislative opioid advisory council to weigh in on appropriations of settlement dollars. “They have published multiple reports with multiple recommendations. None of their recommendations include clinical trials for a new drug, but they do include things like recovery housing or legalizing syringe access programs…or decriminalizing fentanyl test stripes,” Rheingans said, emphasizing that she has separate bills introduced to address those areas. “If we’re going to spend $50 million of opioid settlement funds, we should spend it on recovery housing or other allowable uses, such as paying for clinicians to go get education to learn how to treat opioid use disorder.” This story was first published by Michigan Advance. Photo courtesy of Scamperdale. The post Michigan Lawmakers Debate Bill To Fund Psychedelic Research Using Opioid Settlement Dollars appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

We have sell some products of different custom boxes.it is very useful and very low price please visits this site thanks and please share this post with your friends. แทงบอล

We have sell some products of different custom boxes.it is very useful and very low price please visits this site thanks and please share this post with your friends. แทงบอล